Alloreactive Cellular Strategies for Targeted Leukemia Immunotherapy Via Transient Donor Cell Engagement

Dr. Jacob N. Thompson; Dr. Fatima Al-Mansouri

doi:10.55640/

Open Access

Alloreactive Cellular Strategies for Targeted Leukemia Immunotherapy Via Transient Donor Cell Engagement

https://doi.org/10.55640/

PDF

Dr. Jacob N. Thompson ¹ , Dr. Fatima Al-Mansouri ¹ ,

⁴ Division of Infectious Diseases, University of Toronto, Canada

⁴ Department of Immunology and Women’s Health, Qatar University, Doha, Qatar

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for hematological malignancies, with graft-versus-leukemia (GVL) effects playing a crucial role in disease eradication. This article reviews the principles of cellular immunotherapy, focusing on exploiting alloreactivity to induce anti-leukemic responses while minimizing prolonged donor cell persistence and associated graft-versus-host disease (GVHD). We discuss the mechanisms of alloreactivity, the clinical evidence supporting this approach, and future directions for optimizing cellular immunotherapy strategies.

Keywords

Allogeneic hematopoietic stem cell transplantation (allo-HSCT), graft-versus-host disease (GVHD)

References

📄 D’Orsogna, L.J.; Nguyen, T.H.; Claas, F.H.; Witt, C.; Mifsud, N.A. Endogenous-peptide-dependent alloreactivity: New scientific insights and clinical implications. Tissue Antigens 2013, 81, 399–407.

📄 Blazar, B.R.; Murphy, W.J.; Abedi, M. Advances in graft-versus-host disease biology and therapy. Nat. Rev. Immunol. 2012, 12, 443–458.

📄 Weiden, P.L.; Flournoy, N.; Thomas, E.D.; Prentice, R.; Fefer, A.; Buckner, C.D.; Storb, R. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 1979, 300, 1068–1073.

📄 Kolb, H.J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008, 112, 4371–4383.

📄 Bar, M.; Sandmaier, B.M.; Inamoto, Y.; Bruno, B.; Hari, P.; Chauncey, T.; Martin, P.J.; Storb, R.; Maloney, D.G.; Storer, B.; et al. Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: Prognostic relevance of the initial CD3+ T cell dose. Biol. Blood Marrow Transplant. 2013, 19, 949–957.

📄 Dey, B.R.; McAfee, S.; Colby, C.; Cieply, K.; Caron, M.; Saidman, S.; Preffer, F.; Shaffer, J.; Tarbell, N.; Sackstein, R.; et al. Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation. Br. J. Haematol. 2005, 128, 351–359.

📄 Rubio, M.T.; Kim, Y.M.; Sachs, T.; Mapara, M.; Zhao, G.; Sykes, M. Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusion in mixed chimeras prepared with nonmyeloablative conditioning: Critical role for recipient-derived IFN-gamma. Blood 2003, 102, 2300–2307.

📄 Rubio, M.T.; Saito, T.I.; Kattleman, K.; Zhao, G.; Buchli, J.; Sykes, M. Mechanisms of the antitumor responses and host-versus-graft reactions induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: A critical role for recipient CD4+ T cells and recipient leukocyte infusion-derived IFN-gamma-producing CD8+ T cells. J. Immunol. 2005, 175, 665–676.

📄 Saito, T.I.; Li, H.W.; Sykes, M. Invariant NKT cells are required for antitumor responses induced by host-versus-graft responses. J. Immunol. 2010, 185, 2099–2105.

📄 Saito, T.I.; Rubio, M.T.; Sykes, M. Clinical relevance of recipient leukocyte infusion as antitumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantation. Exp. Hematol. 2006, 34, 1271–1277.

📄 Symons, H.J.; Levy, M.Y.; Wang, J.; Zhou, X.; Zhou, G.; Cohen, S.E.; Luznik, L.; Levitsky, H.I.; Fuchs, E.J. The allogeneic effect revisited: Exogenous help for endogenous, tumor-specific T cells. Biol. Blood Marrow Transplant. 2008, 14, 499–509.

📄 Colvin, G.A.; Berz, D.; Ramanathan, M.; Winer, E.S.; Fast, L.; Elfenbein, G.J.; Quesenberry, P.J. Nonengraftment haploidentical cellular immunotherapy for refractory malignancies: Tumor responses without chimerism. Biol. Blood Marrow Transplant. 2009, 15, 421–431.

📄 Guo, M.; Hu, K.X.; Yu, C.L.; Sun, Q.Y.; Qiao, J.H.; Wang, D.H.; Liu, G.X.; Sun, W.J.; Wei, L.; Sun, X.D.; et al. Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Blood 2011, 117, 936–941.

📄 Guo, M.; Hu, K.X.; Liu, G.X.; Yu, C.L.; Qiao, J.H.; Sun, Q.Y.; Qiao, J.X.; Dong, Z.; Sun, W.J.; Sun, X.D.; et al. HLA-mismatched stem-cell microtransplantation as postremission therapy for acute myeloid leukemia: Long-term follow-up. J. Clin. Oncol. 2012, 30, 4084–4090.

📄 Byrd, J.C.; Mrozek, K.; Dodge, R.K.; Carroll, A.J.; Edwards, C.G.; Arthur, D.C.; Pettenati, M.J.; Patil, S.R.; Rao, K.W.; Watson, M.S.; et al. retreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100, 4325–4336.

📄 Fast, L.D. Recipient CD8+ cells are responsible for the rapid elimination of allogeneic donor lymphoid cells. J. Immunol. 1996, 157, 4805–4810.

📄 Fast, L.D. Recipient elimination of allogeneic lymphoid cells: Donor CD4(+) cells are effective alloantigen-presenting cells. Blood 2000, 96, 1144–1149.

📄 D’Orsogna, L.J.; van den Heuvel, H.; van der Meer-Prins, E.M.; Roelen, D.L.; Doxiadis, II; Claas, F.H. Stimulation of human EBV- and CMV-specific cytolytic effector function using allogeneic HLA molecules. J. Immunol. 2012, 189, 4825–4831.

📄 Brehm, M.A.; Daniels, K.A.; Priyadharshini, B.; Thornley, T.B.; Greiner, D.L.; Rossini, A.A.; Welsh, R.M. Allografts stimulate cross-reactive virus-specific memory CD8 T cells with private specificity. Am. J. Transplant. 2010, 10, 1738–1748.

📄 Morris, G.P.; Allen, P.M. Cutting edge: Highly alloreactive dual TCR T cells play a dominant role in graft-versus-host disease. J. Immunol. 2009, 182, 6639–6643.

📄 Morris, G.P.; Uy, G.L.; Donermeyer, D.; Dipersio, J.F.; Allen, P.M. Dual receptor T cells mediate pathologic alloreactivity in patients with acute graft-versus-host disease. Sci. Transl. Med. 2013, 5, 188ra174.

📄 Lask, A.; Goichberg, P.; Cohen, A.; Goren-Arbel, R.; Milstein, O.; Aviner, S.; Feine, I.; Ophir, E.; Reich-Zeliger, S.; Hagin, D.; et al. TCR-independent killing of B cell malignancies by anti-third-party CTLs: The critical role of MHC-CD8 engagement. J. Immunol. 2011, 187, 2006–2014.

📄 Lask, A.; Ophir, E.; Or-Geva, N.; Cohen-Fredarow, A.; Afik, R.; Eidelstein, Y.; Reich-Zeliger, S.; Nathansohn, B.; Edinger, M.; Negrin, R.S.; et al. A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cells. Blood 2013, 121, 3033–3040.

How to Cite

Alloreactive Cellular Strategies for Targeted Leukemia Immunotherapy Via Transient Donor Cell Engagement. (2025). Global Journal of Medical and Pharmaceutical Sciences, 4(05), 1-6. https://doi.org/10.55640/